Real-world inflammatory bowel disease-modification outcomes: A narrative review
World Journal of Gastroenterology · 14.09.2026 · 32 (34)
DOI: 10.3748/wjg.117240 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.09.2026. Verfasst von Neeraj Narula und 2 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBDs) culminate in disease progression in many patients. Characterized by chronic inflammation and gastrointestinal damage, IBD negatively impacts quality of life, often requires surgery, and can result in disability. Disease modification has been a target for treatment for other chronic inflammatory diseases, and disease-modification trials will help determine if this approach can prevent disease progression in IBD. The standard protocol items: Recommendations for interventional trials (SPIRIT) consensus has recommended disease-modification endpoints for use in clinical trials, but before such studies are conducted, real-world data can be informative. This review of real-world studies in patients with ulcerative colitis or Crohn’s disease treated with advanced treatments that employed the SPIRIT endpoints identified considerable gaps in the use of recommended disease-modification endpoints. Specifically, no studies used the recommended outcomes for midterm complications of fecal incontinence or bowel damage, or assessed macroscopic proximal disease extension, permanent stoma, or short-bowel symptoms. Long-term complications of cancer or mortality were not assessed over the recommended 5-year period. Additionally, studies have not assessed quality of life using the recommended composite of the 36-Item IBD Questionnaire and 36-Item Short-Form Health Survey. In conclusion, there remains a need to incorporate SPIRIT-recommended disease-modification endpoints in prospective real-world studies in patients with IBD receiving advanced treatments.
Zitieren
APA
Narula, N., Adsul, S., & Reinisch, W. (2026). Real-world inflammatory bowel disease-modification outcomes: A narrative review. World Journal of Gastroenterology, 32(34). https://doi.org/10.3748/wjg.117240
Vancouver
Narula N, Adsul S, Reinisch W. Real-world inflammatory bowel disease-modification outcomes: A narrative review. World Journal of Gastroenterology. 2026;32(34). doi:10.3748/wjg.117240
BibTeX
@article{Narula2026,
author = {Narula, Neeraj and Adsul, Shashi and Reinisch, Walter},
title = {Real-world inflammatory bowel disease-modification outcomes: A narrative review},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {34},
doi = {10.3748/wjg.117240}
}
EUVIMED